Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?

Published on Feb 1, 2021in The Breast3.754
· DOI :10.1016/J.BREAST.2020.12.004
Andrei Fodor13
Estimated H-index: 13
,
Chiara Brombin15
Estimated H-index: 15
(UniSR: Vita-Salute San Raffaele University)
+ 24 AuthorsN. Di Muzio12
Estimated H-index: 12
(UniSR: Vita-Salute San Raffaele University)
Sources
Abstract
Abstract Aim We report molecular subtype impact on 1325 early breast cancer (BCa) patients treated with whole breast hypofractionated (WBH) adjuvant forward-planned intensity modulated radiotherapy (F-IMRT) without boost. Methods and materials From 02/2009-05/2017 1325 patients with pTis-pT3, pNx-N1aM0 BCa who underwent breast conservation surgery were treated with WBHF-IMRT in our institute, to a total dose of 40 Gy/15 fractions, without boost. Median age: 62 (interquartile range-IQR-:51.14–70.53) years. Histology: 8% in situ carcinoma (ISC), 92% invasive tumors. Molecular subtypes (invasive tumors): 49.9% Luminal A, 33.1% Luminal B Her2 negative (−), 6.2% Luminal B Her2 positive (+), 3.6% Hormone Receptor (HR)- Her2+, 7.1% Triple negative (TNBC), and 0.2% HR+. Chemotherapy (CT) was prescribed in 28% of patients, hormonal therapy in 80.3%, monoclonal antibodies (MAb) in 86.8% of Luminal B Her2+ and 97.7% of HR- Her2+ patients. Results Median follow up was 72.43 (IQR: 44.63–104.13) months. The 5-year Kaplan-Meier estimates of local relapse-free survival (LRFS) was 97.8%, regional-(RRFS) 98.6%, loco-regional- (LRRFS) 96.9%, distant- (DRFS) 96.6%, disease-free survival (DFS) 94.8% and overall survival (OS) 95.5%. Considering molecular subtypes, 5-year LRFS was: 99.8% for Luminal A, 96.7% for Luminal B Her2-, 94.1% for Luminal B Her2+, 87.9% for HR- Her2+, 95.1% for TNBC and 99.1% for in situ carcinoma. Conclusion While the overall estimated probability of LR within 5 years after WBHF-IMRT without boost is good (2.2%), molecular subtypes have a strong impact, despite MAb therapy in Her2+ patients, and CT for TNBC patients, and could be used as a parameter in deciding the boost prescription.
References47
Newest
#1Alice Y. Ho (Harvard University)H-Index: 29
#2Jean L. Wright (Johns Hopkins University)H-Index: 19
Last. Gaorav P. Gupta (UNC: University of North Carolina at Chapel Hill)H-Index: 24
view all 22 authors...
: Immunotherapy using immune checkpoint blockade has revolutionized the treatment of many types of cancer. Radiation therapy (RT)--particularly when delivered at high doses using newer techniques - may be capable of generating systemic anti-tumor effects when combined with immunotherapy in breast cancer. These systemic effects might be due to the local immune-priming effects of RT resulting in the expansion and circulation of effector immune cells to distant sites. While this concept merits furt...
4 CitationsSource
#1Dat Nguyen (NIH: National Institutes of Health)H-Index: 8
Last. Sherry X. YangH-Index: 22
view all 4 authors...
Importance It is not well understood whether prognostic factors in breast cancer are affected by specific treatment and vary by clinical outcome type compared with untreated patients. Objective To identify independent clinical and molecular measurements associated with overall survival (OS) and recurrence-free survival (RFS) by homogeneous treatment in women with breast cancer. Design, Setting, and Participants This prognostic study included 956 patients diagnosed with invasive breast cancer fro...
6 CitationsSource
#1Fabiana GregucciH-Index: 9
#3Sara FaliveneH-Index: 9
Last. Antonella CiabattoniH-Index: 1
view all 8 authors...
To investigate the present attitude of the Italian Radiation Oncologists in the management of breast cancer (BC) concerning hypofractionated radiotherapy (hRT), partial-breast irradiation (PBI), re-irradiation (rRT) and radiotherapy after neoadjuvant chemotherapy (post-NAC RT). A nationwide, 21-point questionnaire was distributed online via SurveyMonkey. Seventy-four Italian Radiotherapy Centers answered to the survey. In most cases, the responding centers treated more than 100 BC patients/year ...
7 CitationsSource
#1Mathieu Césaire (UNICAEN: University of Caen Lower Normandy)H-Index: 3
#2Juliette ThariatH-Index: 28
Last. François Chevalier (UNICAEN: University of Caen Lower Normandy)H-Index: 22
view all 6 authors...
Immunotherapy has revolutionized the practice of oncology, improving survival in certain groups of patients with cancer. Immunotherapy can synergize with radiation therapy, increase locoregional control, and have abscopal effects. Combining it with other treatments, such as targeted therapies, is a promising means of improving the efficacy of immunotherapy. Because the value of immunotherapy is amplified with the expression of tumor antigens, coupling poly(ADP-ribose) polymerase (PARP) inhibitor...
27 CitationsSource
#1Pelagia G. TsoutsouH-Index: 13
#1P. Tsoutsou (CHUV: University Hospital of Lausanne)H-Index: 2
Last. Jean Bourhis (CHUV: University Hospital of Lausanne)H-Index: 17
view all 4 authors...
Abstract Systemic treatments are tailored to breast cancer (BC) heterogeneity, which is not yet taken into account for radiotherapy (RT) personalization. The primary objective of this review is to summarize existing data suggesting BC subtypes and genetic assays are prognostic and predictive biomarkers useful for RT decision-making and to provide implications for their incorporation into future translational and clinical research. The evidence suggesting that BC subtypes also exhibit distinct “l...
23 CitationsSource
#1Anna EhingerH-Index: 17
#2Per MalmströmH-Index: 34
Last. Mårten FernöH-Index: 70
view all 10 authors...
Background: The St Gallen surrogate definition of the intrinsic subtypes of breast cancer consist of five subgroups based on estrogen receptor (ER), progesterone receptor (PgR), human epidermal gro ...
24 CitationsSource
#1Conny VrielingH-Index: 13
#2Erik van Werkhoven (NKI-AVL: Netherlands Cancer Institute)H-Index: 25
Last. Harry Bartelink (NKI-AVL: Netherlands Cancer Institute)H-Index: 91
view all 24 authors...
Importance Prognostic factors of ipsilateral breast tumor recurrence (IBTR) may change over time following breast-conserving therapy. Objective The EORTC “boost no boost” trial showed that young age and high-grade invasive carcinoma were the most important risk factors for IBTR. This study reanalyses pathological prognostic factors related to IBTR using long-term follow-up. Design, Setting, and Participants Participants included 5569 early-stage breast cancer patients, treated with breast-conser...
66 CitationsSource
#1Monica Morrow (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 103
#2Kimberly J. Van Zee (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 59
Last. Meena S. Moran (Yale University)H-Index: 34
view all 13 authors...
BackgroundControversy exists regarding the optimal negative margin width for ductal carcinoma in situ (DCIS) treated with breast-conserving surgery and whole-breast irradiation (WBRT).MethodsA multidisciplinary consensus panel used a meta-analysis of margin width and ipsilateral breast tumor recurrence (IBTR) from a systematic review of 20 studies including 7883 patients and other published literature as the evidence base for consensus.ResultsNegative margins halve the risk of IBTR compared with...
181 CitationsSource
#1André Hennigs (Heidelberg University)H-Index: 12
#2Fabian Riedel (Heidelberg University)H-Index: 7
Last. Andreas Schneeweiss (Heidelberg University)H-Index: 75
view all 16 authors...
Background In Germany, most breast cancer patients are treated in specialized breast cancer units (BCU), which are certified, and routinely monitored. Herein, we evaluate up-to-date oncological outcome of breast cancer (BC) molecular subtypes in routine clinical care of a specialized BCU.
62 CitationsSource
#1Zhi-hua LiH-Index: 1
#2Ping-hua HuH-Index: 1
Last. Ni-si YuH-Index: 1
view all 4 authors...
// Zhi-hua Li 1 , Ping-hua Hu 1 , Jian-hong Tu 2 , Ni-si Yu 3 1 Prevention and Cure Center of Breast Disease, The Third Hospital of Nanchang City, Key Laboratory Of Breast Diseases In Jiangxi Province, Nanchang, JiangXi 330009, People’s Republic of China 2 Department of Pathology, The Third Hospital of Nanchang City, JiangXi Breast Specialist Hospital, Nanchang, JiangXi 330009, People’s Republic of China 3 Department of Gynaecology, The Affiliated Hospital of Jiangxi Traditional Chinese Medicine...
32 CitationsSource
Cited By0
Newest